LXRX News and Press, Lexicon Pharmaceuticals Inc. From 04/22/23

2023-04-22 08:15:00 ET Biotech companies yet to generate revenue are some of the riskiest growth stocks out there, but if you can invest in one while it's taking off, your portfolio will thank you. On that note, according to analysts on Wall Street, shares of Lexicon Pharmaceuticals ...

THE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of postherpetic neuralgia, will be p...

THE WOODLANDS, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17-20, 2023. Lonnel Coats, Lexicon’s chief executive officer, Jeffrey...

2023-03-07 11:24:57 ET "We do think the [heart failure with preserved ejection fraction (HFpEF)] subpopulation is a relatively attractive opportunity [vs heart failure with reduced ejection fraction (HFrEF)], but having to compete against AstraZeneca's ( AZN ) Farxiga and Eli...

2023-03-05 02:23:39 ET Summary Lexicon is getting closer to FDA approval for sotagliflozin, and the ongoing labeling discussions with the agency may prove critical in differentiating the drug from established rivals. Sotagliflozin may be superior in terms of reducing hospitalizati...

Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection fraction (LVEF) range THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: ...

Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American College of Cardiolo...

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Carrie Siragusa – Executive Director, Corporate Strategy and Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – P...

Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q4 GAAP EPS of -$0.16 misses by $0.03 . Revenue of $0.03M (+200.0% Y/Y) misses by $0.02M . For further details see: Lexicon Pharmaceuticals GAAP EPS of -$0.16 misses by $0.03, revenue of $0.03M misses by $0.02M

NDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia Confere...